Articles from NeuraNova, Inc.

NeuraNova, Inc., a medical technology company developing portable, noninvasive technologies for neurological care, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance to the STEDI Device. The STEDI Device is a bioimpedance spectroscopy device designed to measure impedance ratios, aiding in the assessment of cerebral fluid volume asymmetry between the cerebral hemispheres in adult patients undergoing neurological assessment. The STEDI Device is an adjunct to standard clinical evaluation methodologies. The clearance represents a defining milestone for NeuraNova, previously known as StrokeDx Inc., and years of focused work by its scientists, engineers, clinicians, study teams, advisors, partners, and supporters.